Three phase 3 trials presented at the 2026 ESMO Congress looked closely at swallowing, daily functioning and blood counts in throat, kidney and colorectal cancer. Here is what they found about living well during and after treatment.
|Articles|May 7, 2021
Rage at the Sun
Author(s)Robin Zimmerman
A melanoma survivor pens a poem about his cancer journey, losing his wife to melanoma and how he lives his life after these experiences.
Advertisement
You took my wife and the mother of our children
and replaced her with pain and sorrow.
You took flesh from my back
and gave me the fear of a simple walk in the park.
My children and I grieved and healed.
My doctor treated my wound and we monitor my skin.
We now leave the house and enjoy the day
with the protection of glasses, clothing, hats and lotions.
With knowledge and awareness, we now survive.
We spread the word to help others avoid our pain.
Now we party and shout and dance in the park.
Then we look to the sky and Rage at the Sun.
For more news on cancer updates, research and education, don’t forget to
Advertisement
Related to this article
New research found that nearly 1 in 5 second-level appeals for denied cancer medications under Medicare Part D were successful, raising questions about how insurers make coverage decisions and what patients can do when their treatment is denied.
Joy Maulik, MSN, FNP-C, explains why a prostate cancer diagnosis should be seen as a change in direction, not an ending, and how patients can lean on education, their providers and caregivers.
Dr. Morana Vojnic answers common questions about brain cancer, including diagnosis, tumor types, treatment effects, recurrence and life after treatment begins.
A national survey study of about 200,000 adults, published in Supportive Care in Cancer, found that people caring for someone with cancer had 89% higher odds of frequent mental distress than people who were not caregivers.
Longer follow-up presented at the 2026 ESMO Congress showed that four already-approved treatments for early breast cancer, kidney cancer, colorectal cancer and stomach and esophageal cancer kept helping patients years later.
Dr. Jacqueline Barrientos shares how a targeted therapy, a determined care team and a stranger’s generosity gave a 72-year-old man with hairy cell leukemia and kidney failure a second chance.
A clinical trial will test zanubrutinib plus sonrotoclax as a fixed-duration, chemotherapy-free treatment for hairy cell leukemia, aiming for undetectable disease.
Advertisement
Advertisement
Trending on CURE
1
Top 5 Takeaways From ESMO 2026 That Patients Should Know
2
4 Long-Term Survival Results From ESMO 2026 Patients Should Know
3
Neuro-Oncologist Answers Common Questions About Brain Cancer Diagnosis and Treatment
4
Life After a Prostate Cancer Diagnosis: Why It’s a Pivot, Not an Ending
5